Clinical trial
Bortezomib in Treating Patients With Lymphoproliferative Disorders
NCT00023764 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00023764 |
|---|---|
| Title | Bortezomib in Treating Patients With Lymphoproliferative Disorders |
| Official title | Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 103 |
| Start date | Jun 1, 2001 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 8, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: